Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluGuard versus Vaxigrip Tetra in healthy adolescents for seasonal influenza immunogenicity and safety
IRCT20240626062259N2Phase 3Completed
- Sponsor
- Nivad Pharmed Salamat
- Start
- Sep 2024
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of favipiravir and quadrivalent influenza vaccine in seasonal influenza (2 arms), sponsored by Nivad Pharmed Salamat. Primary endpoints: Geometric mean titer ratio for hemagglutinin antibodies and Seroconversion rate. Started Sep 2024; status: completed.
02
Drugs
favipiravirquadrivalent influenza vaccine
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on IRCT20240626062259N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240626062259N2.